Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

S-adenosyl methionine decarboxylase activity is required for the outcome of herpes simplex virus type 1 infection and represents a new potential therapeutic target.

Greco A, Callé A, Morfin F, Thouvenot D, Cayre M, Kindbeiter K, Martin L, Levillain O, Diaz JJ.

FASEB J. 2005 Jul;19(9):1128-30. Epub 2005 Apr 28.

PMID:
15863396
2.

Novel targets for the development of anti-herpes compounds.

Greco A, Diaz JJ, Thouvenot D, Morfin F.

Infect Disord Drug Targets. 2007 Mar;7(1):11-8. Review.

PMID:
17346207
3.
4.

Beta interferon plus gamma interferon efficiently reduces acyclovir-resistant herpes simplex virus infection in mice in a T-cell-independent manner.

Huang WY, Su YH, Yao HW, Ling P, Tung YY, Chen SH, Wang X, Chen SH.

J Gen Virol. 2010 Mar;91(Pt 3):591-8. doi: 10.1099/vir.0.016964-0. Epub 2009 Nov 11.

PMID:
19906941
5.

Antiviral activity of a selective ribonucleotide reductase inhibitor against acyclovir-resistant herpes simplex virus type 1 in vivo.

Duan J, Liuzzi M, Paris W, Lambert M, Lawetz C, Moss N, Jaramillo J, Gauthier J, Déziel R, Cordingley MG.

Antimicrob Agents Chemother. 1998 Jul;42(7):1629-35.

6.

Cytopathic effect inhibition assay for determining the in-vitro susceptibility of herpes simplex virus to antiviral agents.

Cotarelo M, Catalán P, Sánchez-Carrillo C, Menasalvas A, Cercenado E, Tenorio A, Bouza E.

J Antimicrob Chemother. 1999 Nov;44(5):705-8.

PMID:
10552991
7.

Expression of herpes simplex virus type 1 recombinant thymidine kinase and its application to a rapid antiviral sensitivity assay.

Shiota T, Lixin W, Takayama-Ito M, Iizuka I, Ogata M, Tsuji M, Nishimura H, Taniguchi S, Morikawa S, Kurane I, Mizuguchi M, Saijo M.

Antiviral Res. 2011 Aug;91(2):142-9. doi: 10.1016/j.antiviral.2011.05.015. Epub 2011 Jun 2.

PMID:
21669227
9.

Efficacy of Cafon gel on cutaneous infection with herpes simplex virus (HSV)-2 and acyclovir-resistant HSV in mice.

Yoshida Y, Yamamura J, Sato H, Koyasu M, Obara Y, Sekiguchi H, Kawana T, Shiraki K.

J Dermatol Sci. 1996 Dec;13(3):237-41.

PMID:
9023706
10.

Phenotypic and genotypic characterization of acyclovir-resistant herpes simplex viruses from immunocompromised patients.

Gaudreau A, Hill E, Balfour HH Jr, Erice A, Boivin G.

J Infect Dis. 1998 Aug;178(2):297-303.

PMID:
9697707
11.

Frequency of acyclovir-resistant herpes simplex viruses isolated from the general immunocompetent population and patients with acquired immunodeficiency syndrome.

Ziyaeyan M, Alborzi A, Japoni A, Kadivar M, Davarpanah MA, Pourabbas B, Abassian A.

Int J Dermatol. 2007 Dec;46(12):1263-6. doi: 10.1111/j.1365-4632.2007.03449.x.

PMID:
18173520
12.

Activity of penciclovir in antiviral assays against herpes simplex virus.

Bacon TH, Howard BA, Spender LC, Boyd MR.

J Antimicrob Chemother. 1996 Feb;37(2):303-13.

PMID:
8707740
13.

[Analysis of mutations in DNA polymerase and thymidine kinase genes of herpes simplex virus clinical isolates resistant to antiherpetic drugs].

Korovina AN, Gus'kova AA, Skoblov MIu, Andronova VL, Galegov GA, Kochetkov SN, Kukhanova MK, Skoblov IuS.

Mol Biol (Mosk). 2010 May-Jun;44(3):488-96. Russian.

PMID:
20608173
14.

[Anti alpha-herpesvirus drugs].

Koshizuka T, Suzutani T.

Nihon Rinsho. 2012 Apr;70(4):558-63. Review. Japanese.

PMID:
22568134
15.

Suppression of generation and replication of acyclovir-resistant herpes simplex virus by a sensitive virus.

Okuda T, Kurokawa M, Matsuo K, Honda M, Niimura M, Shiraki K.

J Med Virol. 2004 Jan;72(1):112-20.

PMID:
14635018
16.
17.

Drug targets in herpes simplex and Epstein Barr Virus infections.

Billaud G, Thouvenot D, Morfin F.

Infect Disord Drug Targets. 2009 Apr;9(2):117-25. Review.

PMID:
19275700
18.

[Resistance to virostatic agents in Herpes viruses: mechanism, incidence and clinical significance].

Reusser P.

Schweiz Med Wochenschr. 1994 Jan 29;124(4):152-8. German. Erratum in: Schweiz Med Wochenschr 1994 Feb 26;124(8):346.

PMID:
8128197
19.

Herpes simplex virus resistance to acyclovir: clinical relevance.

Pottage JC Jr, Kessler HA.

Infect Agents Dis. 1995 Sep;4(3):115-24. Review.

PMID:
8548189
20.

Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease.

Crute JJ, Grygon CA, Hargrave KD, Simoneau B, Faucher AM, Bolger G, Kibler P, Liuzzi M, Cordingley MG.

Nat Med. 2002 Apr;8(4):386-91.

PMID:
11927945

Supplemental Content

Support Center